Development and validation of a EULAR disease activity score in antiphospholipid syndrome
Annals of the Rheumatic Diseases · 2026
DOI: 10.1016/j.ard.2025.10.006 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Maria G Tektonidou und 24 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian…. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Severity of Illness Index. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche, European Alliance of Associations for Rheumatology.
Abstract (Originalsprache)
OBJECTIVES: To develop and validate a European Alliance of Associations for Rheumatology (EULAR) disease activity score in antiphospholipid syndrome (EAPSDAS). METHODS: Twenty-four Task Force members and an international group of 53 antiphospholipid syndrome (APS) experts/collaborators, 65 patients with primary APS, and 21 healthcare professionals participated. EAPSDAS development proceeded in 4 phases: (i) item generation using a systematic literature review and 2 surveys; (ii) item reduction by rating items on their importance to be included in EAPSDAS and using Delphi methodology; (iii) item scoring based on real-world clinical vignettes and using as criterion standard the physician global assessment (PhysGA); and (iv) validation. RESULTS: One hundred seventy items representing APS activity were generated, and 140 deduplicated candidate items were rated by participants. Using a ≥75% vote threshold and Delphi consensus among Task Force members, 24 items were included in the EAPSDAS thrombotic/microvascular/nonthrombotic (TMN) scale and 6 in the obstetric scale. Item scoring was based on ratings of 3 versions of 60 vignettes with new/worsening manifestations (30 single TMN or obstetric manifestations, 26 combinations of 2 TMN manifestations, 2 inactive cases, 2 testing cases) by physicians. Item scores were calculated as the adjusted mean PhysGA in linear regression analysis. A 1-month time frame was defined for the TMN scale and the entire pregnancy for the obstetric scale. Scores for stable or improved TMN manifestations were also included. High face and content validity, construct validity (internal/external standard), and reliability were demonstrated using real-world clinical vignettes. CONCLUSIONS: Using data-driven and consensus methodology, EAPSDAS was developed and initial validation was performed. Further validation in prospective studies is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mtektonidou…
- Department of Autoimmune Diseases, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain.
- Rheumatology and Clinical Immunology Unit-ERN ReCONNET, ASST-Spedali Civili and University of Brescia, Brescia, Italy.
- Department of Rheumatology, Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina.
- University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member), University of Turin, Turin, Italy.
- Systemic Autoimmune Diseases Unit and Systemic Autoimmune Diseases Research Unit, Vall d' Hebron University Hospital, and Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Förderung
- Roche
- European Alliance of Associations for Rheumatology
Zitieren
APA
Tektonidou, M. G., Cervera, R., Tincani, A., Pons-Estel, G. J., Sciascia, S., Alijotas-Reig, J., Avcin, T., Bertolaccini, M. L., Jasinski, T., Marchiori, F., Mekinian, A., Meroni, P. L., Pengo, V., Radin, M., Rahman, A., Ruiz-Irastorza, G., Schreiber, K., Stoilova, S., van den Hoogen, L., …, & EULAR APS Disease Activity Score Collaborators (2026). Development and validation of a EULAR disease activity score in antiphospholipid syndrome. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.10.006
Vancouver
Tektonidou MG, Cervera R, Tincani A, Pons-Estel GJ, Sciascia S, Alijotas-Reig J, et al. Development and validation of a EULAR disease activity score in antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2025.10.006
BibTeX
@article{Tektonidou2026,
author = {Tektonidou, Maria G and Cervera, Ricard and Tincani, Angela and Pons-Estel, Guillermo J and Sciascia, Savino and Alijotas-Reig, Jaume and Avcin, Tadej and Bertolaccini, Maria Laura and Jasinski, Tiina and Marchiori, Francesca and Mekinian, Arsene and Meroni, Pier-Luigi and Pengo, Vittorio and Radin, Massimo and Rahman, Anisur and Ruiz-Irastorza, Guillermo and Schreiber, Karen and Stoilova, Stefka and van den Hoogen, Lucas and van Vollenhoven, Ronald and Wahl, Denis and Stamm, Tanja and Landewé, Robert B M and Ward, Michael M and EULAR APS Disease Activity Score Collaborators, EULAR APS Disease Activity Score Collaborators},
title = {Development and validation of a EULAR disease activity score in antiphospholipid syndrome},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
doi = {10.1016/j.ard.2025.10.006}
}
EUVIMED